康寧醫院(02120.HK)董事會審議通過發行A股於創業板上市議案
格隆匯8月6日丨康寧醫院(02120.HK)公吿,為更好地為廣大民眾提供優質的醫療服務,把握中國經濟快速增長帶來的發展機遇,同時不斷增強公司的核心競爭力和影響力,公司擬申請A股發行並在深交所創業板上市。公司已於2021年8月6日召開的董事會會議上通過了關於首次公開發行人民幣普通股(A股)股票並在創業板上市的議案。
本次發行上市全部為公開發行新股,公司原股東在本次發行上市中不涉及出售股份。公司本次擬向社會公開發行不超過828.8922萬股的人民幣普通股(A股),公開發行股票數量不超過本次發行後公司股本總額的10%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.